Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 3, 2009, Pages 190-193

  Hasegawa, Naoki ^a   Nishimura, Tomoyasu ^a   Watabnabe, Masazumi ^a   Tasaka, Sadatomo ^a   Nakano, Yasushi ^a   Yamazaki, Koichi ^b   Hashimoto, Satoru ^c   Nishimura, Masahiro ^b   Ishizaka, Akitoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antimicrobial concentration; Bronchoscopic microsampling; Clarithromycin; Epithelial lining fluid; Mycobacterium avium complex

Indexed keywords

14 HYDROXYCLARITHROMYCIN; CLARITHROMYCIN; DRUG METABOLITE;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BRONCHOSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; HUMAN; LUNG ALVEOLUS EPITHELIUM; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL;

AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; BIOTRANSFORMATION; BODY FLUIDS; BODY MASS INDEX; BRONCHOSCOPY; CLARITHROMYCIN; EPITHELIUM; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 67349243505     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.11.004     Document Type: Article

References (37)

1. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 (2007) 367-416
2. Marras T.K., and Daley C.L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 23 (2002) 553-567
3. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest 133 (2008) 243-251
4. Sakatani M. Nontuberculous mycobacteriosis: the present status of epidemiology and clinical studies. Kekkaku 74 (1999) 377-384 (in Japanese, with English abstract)
5. Prince D.S., Peterson D.D., Steiner R.M., Gottlieb J.E., Scott R., Israel M.L., et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321 (1989) 863-868
6. Fujita J., Ohtsuki Y., Suemitsu I., Shigeto E., Yamadori I., Obayashi Y., et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease. Eur Respir J 13 (1999) 535-540
7. Wallace Jr. R.J., Brown B.A., Griffith D.E., Girard W.M., and Murphy D.T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 153 (1996) 1766-1772
8. Tanaka E., Kimoto T., Tsuyuguchi K., Watanabe I., Matsumoto H., Niimi A., et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 160 (1999) 866-872
9. Field S.K., Fisher D., and Cowie R.L. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 126 (2004) 566-581
10. Kiem S., and Schentag J.J. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52 (2008) 24-36
11. Tomioka H., Sato K., Sano C., Sano K., and Shimizu T. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. Antimicrob Agents Chemother 46 (2002) 519-521
12. Middleton A.M., Chadwick M.V., Nicholson A.G., Dewar A., Feldman C., and Wilson R. Investigation of mycobacterial colonisation and invasion of the respiratory mucosa. Thorax 58 (2003) 246-251
13. Chu S., Wilson D.S., Deaton R.L., Mackenthun A.V., Eason C.N., and Cavanaugh J.H. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 33 (1993) 719-726
14. Honeybourne D., Kees F., Andrews J.M., Baldwin D., and Wise R. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J 7 (1994) 1275-1280
15. Conte Jr. J.E., Golden J.A., Duncan S., McKenna E., and Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 39 (1995) 334-338
16. Dautzenberg B., Piperno D., Diot P., Truffot-Pernot C., and Chauvin J.P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 107 (1995) 1035-1040
17. Cohen Y., Perronne C., Truffot-Pernot C., Grosset J., Vilde J.L., and Pocidalo J.J. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 36 (1992) 2104-2107
18. Ishizaka A., Watanabe M., Yamashita T., Ogawa Y., Koh H., Hasegawa N., et al. New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome. Crit Care Med 29 (2001) 896-898
19. Yamazaki K., Ogura S., Ishizaka A., Oh-Hara T., and Nishimura M. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med 168 (2003) 1304-1307
20. Kikuchi J., Yamazaki K., Kikuchi E., Ishizaka A., and Nishimura M. Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. Clin Ther 29 (2007) 123-130
21. Kikuchi J., Yamazaki K., Kikuchi E., Ishizaka A., and Nishimura M. Pharmacokinetics of telithromycin using bronchoscopic microsampling after single and multiple oral doses. Pulm Pharmacol Ther 20 (2007) 549-555
22. Kikuchi E., Yamazaki K., Kikuchi J., Hasegawa N., Hashimoto S., Ishizaka A., et al. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. Respirology 13 (2008) 221-226
23. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 156 (1997) S1-S25
24. Wallace Jr. R.J., Brown B.A., Griffith D.E., Girard W., and Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 171 (1995) 747-750
25. Li W., Rettig J., Jiang X., Francisco D.T., and Naidong W. Liquid chromatographic-electrospray tandem mass spectrometric determination of clarithromycin in human plasma. Biomed Chromatogr 20 (2006) 1242-1251
26. Hasegawa N., Miura T., Ishizaka A., Yamaguchi K., and Ishii K. Detection of mycobacteria in patients with pulmonary tuberculosis undergoing chemotherapy using MGIT and egg-based solid medium culture systems. Int J Tuberc Lung Dis 6 (2002) 447-453
27. Kusunoki S., Ezaki T., Tamesada M., Hatanaka Y., Asano K., Hashimto Y., et al. Application of colorimetric microdilution plate hybridization for rapid genetic identification of 22 Mycobacterium species. J Clin Microbiol 29 (1991) 1596-1603
28. Woods GL., Brown-Elliott BA., Desmond EP., Hall GS., Heifets L., Pfyffer GE., et al. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standards (2003), NCCLS document M24-A
29. Tsang K.W., Roberts P., Read R.C., Kees F., Wilson R., and Cole P.J. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. J Antimicrob Chemother 33 (1994) 289-297
30. Patel K.B., Xuan D., Tessier P.R., Russomanno J.H., Quintiliani R., and Nightingale C.H. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40 (1996) 2375-2379
31. Hardy D.J., Swanson R.N., Rode R.A., Marsh K., Shipkowitz N.L., and Clement J.J. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 34 (1990) 1407-1413
32. Vallee E., Azoulay-Dupuis E., Swanson R., Bergogne-Berezin E., and Pocidalo J.J. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J Antimicrob Chemother 27 Suppl. A (1991) 31-41
33. Martin S.J., Garvin C.G., McBurney C.R., and Sahloff E.G. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47 (2001) 581-587
34. Mor N., Vanderkolk J., and Heifets L. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. Pharmacotherapy 14 (1994) 100-104
35. Truffot-Pernot C., Ji B., and Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother 35 (1991) 1677-1678
36. Chu S.Y., Sennello L.T., Bunnell S.T., Varga L.L., Wilson D.S., and Sonders R.C. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 36 (1992) 2447-2453
37. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081